These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 10810787)

  • 1. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of action of class III anti-arrhythmia agents].
    Adamantidis MM
    Arch Mal Coeur Vaiss; 1995 Jan; 88 Spec No 1():33-40. PubMed ID: 7786143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Principles for the classification of anti-arrhythmia agents in cardiac arrhythmias].
    Ravens U
    Z Kardiol; 1992; 81 Suppl 4():119-25. PubMed ID: 1290288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ion channels and arrhythmias].
    Borchard U; Hafner D
    Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of cardiac potassium channels.
    Tamargo J; Caballero R; Gómez R; Valenzuela C; Delpón E
    Cardiovasc Res; 2004 Apr; 62(1):9-33. PubMed ID: 15023549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization.
    Cheng JH; Kodama I
    Acta Pharmacol Sin; 2004 Feb; 25(2):137-45. PubMed ID: 14769199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic drug therapy: new drugs and changing concepts.
    Reiser HJ; Sullivan ME
    Fed Proc; 1986 Jul; 45(8):2206-12. PubMed ID: 2873062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiarrhythmic agents. Receptor hypothesis explains mechanisms of action].
    Bjørnstad H; Refsum H
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3187-9. PubMed ID: 1658976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and management of congenital and acquired long QT syndromes.
    Lazzara R
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():51-5. PubMed ID: 8734164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers as antiarrhythmic agents.
    Zicha S; Tsuji Y; Shiroshita-Takeshita A; Nattel S
    Handb Exp Pharmacol; 2006; (171):235-66. PubMed ID: 16610347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New aspects of frequency-dependent effect of class 1 anti-arrhythmia drugs. A critical analysis of useful subclassification].
    Weirich J; Antoni H
    Z Kardiol; 1991 Mar; 80(3):177-86. PubMed ID: 2058249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
    J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.